Moderna, Inc. (NASDAQ:MRNA) Receives $29.21 Average PT from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has earned an average rating of “Reduce” from the nineteen brokerages that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $29.2143.

MRNA has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Berenberg Bank set a $28.00 price target on shares of Moderna in a research report on Monday, November 17th. Bank of America dropped their price target on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, November 10th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Finally, Wolfe Research restated an “underperform” rating and issued a $17.00 price objective on shares of Moderna in a report on Thursday, November 20th.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.

Institutional Trading of Moderna

Institutional investors have recently added to or reduced their stakes in the stock. Rothschild Investment LLC raised its holdings in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares during the last quarter. TD Private Client Wealth LLC increased its position in shares of Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the period. Atlantic Union Bankshares Corp bought a new position in Moderna during the second quarter worth $26,000. SVB Wealth LLC acquired a new position in Moderna in the first quarter valued at $28,000. Finally, Whittier Trust Co. acquired a new position in Moderna in the second quarter valued at $28,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Down 0.2%

NASDAQ MRNA opened at $31.15 on Tuesday. The company has a market cap of $12.17 billion, a price-to-earnings ratio of -3.86 and a beta of 1.11. Moderna has a twelve month low of $22.28 and a twelve month high of $48.92. The business’s fifty day moving average is $27.07 and its 200 day moving average is $27.41.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. During the same quarter in the prior year, the firm earned $0.03 EPS. The business’s revenue for the quarter was down 45.4% compared to the same quarter last year. On average, research analysts anticipate that Moderna will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.